An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Zymeworks Announces Participation in Upcoming Investor Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, will participate in the JP Morgan Healthcare Conference with one-on-one meetings and a corporate presentation on January 12 at 10:30 am PT. The event aims to showcase Zymeworks' innovative biotherapeutics for cancer treatment. The company is advancing candidates like zanidatamab and zanidatamab zovodotin, targeting HER2-expressing cancers. Presentations will be accessible on Zymeworks’ website.
Positive
None.
Negative
None.
VANCOUVER, British Columbia--(BUSINESS WIRE)--
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced that management will participate in an upcoming investor conference:
JP Morgan Healthcare Conference. Zymeworks’ management will participate in one-on-one meetings on January 12th and a corporate presentation on January 12th at 10:30 am Pacific Time (PT).
Zymeworks is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks’ proprietary Azymetric™ technology, which is expected to be commercialized globally by two partners: BeiGene in Asia Pacific (APAC) regions excluding Japan, and Jazz Pharmaceuticals globally excluding APAC. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and pivotal clinical trials as a best-in-class treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Phase 1 clinical trial for patients with a variety of HER2-expressing cancers. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates (ADC) and multispecific antibody therapeutics (MSAT). In addition to Zymeworks’ wholly-owned pipeline, its therapeutic platforms have been further leveraged and validated in product development through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.
When will Zymeworks participate in the JP Morgan Healthcare Conference?
Zymeworks will participate in the JP Morgan Healthcare Conference on January 12, including a corporate presentation at 10:30 am PT.
What is Zymeworks' stock symbol?
Zymeworks' stock symbol is ZYME.
What therapies is Zymeworks developing?
Zymeworks is developing innovative therapies like zanidatamab and zanidatamab zovodotin targeting HER2-expressing cancers.
Where can I find Zymeworks' conference presentations?
Presentations from Zymeworks will be available on their website at ir.zymeworks.com/events-and-presentations.
What is the significance of the JP Morgan Healthcare Conference for Zymeworks?
The JP Morgan Healthcare Conference is significant for Zymeworks as it allows them to present their innovative biotherapeutics and connect with potential investors.
